drugset / Trial / NCT01491958
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
Phase II trial evaluating the safety \& efficacy of Atorvastatin for prophylaxis of Acute Graft Versus Host Disease (GVHD) in patients with hematological malignances undergoing human leukocyte antigen (HLA)-Matched Related Donor Hematopoietic Stem Cell Transplant (HSCT).
Timeline
- Start
- 2011-12-10
- Primary completion
- 2014-01-01
- Completion
- 2016-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | Oral |
| Background | Methotrexate | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |